🎙️✨ Melinda Knows Best at AAD Denver: Hands Down, Chronic Hand Eczema Is Getting a New Playbook 🖐️

Live from AAD 2026 in Denver 🏔️, a podcast favorite, Melinda Knows Best returns with Dr. Melinda Gooderham for a true post-game analysis🏀 of new chronic hand eczema data — and yes, this one is all about helping hands get back to doing what hands do best: opening jars 🥜, buttoning shirts 👔, holding coffee cups ☕, and generally not letting everyday life feel just like a clinical endpoint.

In this episode, we break down new pooled post-hoc data evaluating delgocitinib cream versus vehicle in adults with moderate-to-severe chronic hand eczema, with a practical twist: does prior systemic therapy exposure matter for patient success, especially when it comes to pain and itch? 🤔

We dive into:

• Does this data push delgocitinib earlier in the treatment algorithm for Melinda?
• What are the biggest critiques or caveats a dermatologist should keep in mind when looking at this data?
• Who is the real-world patient you would think about tomorrow after seeing this poster

Well the chronic hand eczema treatment ladder may not be a one-way escalator anymore. 🪜🔄

Dr. Gooderham brings the real-world lens 👩‍⚕️: patients do not just want almost clear skin on a study scale — they want to work, cook, dress, sleep, and live without painful, itchy, fissured hands getting in the way.

Because when it comes to chronic hand eczema, sometimes the most meaningful outcome is being able to open the peanut butter jar without negotiating with your skin first. 🥜😅

Learning objectives 📚
By the end of this episode, listeners will be able to:

1. Summarize new AAD 2026 data evaluating delgocitinib cream in moderate-to-severe chronic hand eczema based on prior systemic therapy exposure.
2. Compare response patterns in systemic-naïve versus systemic-experienced patients.
3. Discuss the real-world clinical relevance of early itch and pain improvement in chronic hand eczema.
4. Identify key caveats of the analysis, including its post-hoc design, subgroup size, and 16-week timeframe.
5. Consider how delgocitinib may fit into evolving treatment algorithms for chronic hand eczema.

#SkinAndJointsPodcast #MelindaKnowsBest #AAD2026 #ChronicHandEczema #HandEczema #EczemaCare #Dermatology #DermatologyPodcast #Delgocitinib #MedicalEducation #HCPeducation #DermTwitter #AADDenver #SkinScience #TopicalTherapy #RealWorldDermatology #IGA #HESD #itch #pain

Episode supported by and IME Grant from LEO Pharma

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.